173 related articles for article (PubMed ID: 23675881)
21. [Kinase inhibitors for the therapy of malignant melanoma].
Becker JC; Schrama D; Bröcker EB; Houben R
J Dtsch Dermatol Ges; 2005 Oct; 3(10):762-7. PubMed ID: 16194153
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
[TBL] [Abstract][Full Text] [Related]
23. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
24. Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy.
Dantonio PM; Klein MO; Freire MRVB; Araujo CN; Chiacetti AC; Correa RG
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30166456
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment.
Read J
Australas J Dermatol; 2013 Aug; 54(3):163-72. PubMed ID: 23330781
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
27. Targeting BRAF in melanoma: biological and clinical challenges.
Mandalà M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
28. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
29. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
[TBL] [Abstract][Full Text] [Related]
30. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.
Steelman LS; Abrams SL; Whelan J; Bertrand FE; Ludwig DE; Bäsecke J; Libra M; Stivala F; Milella M; Tafuri A; Lunghi P; Bonati A; Martelli AM; McCubrey JA
Leukemia; 2008 Apr; 22(4):686-707. PubMed ID: 18337767
[TBL] [Abstract][Full Text] [Related]
31. Molecularly targeted therapy for melanoma: current reality and future options.
Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A
Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502
[TBL] [Abstract][Full Text] [Related]
32. Exogenous administration of visfatin affects cytokine secretion and increases oxidative stress in human malignant melanoma Me45 cells.
Buldak RJ; Polaniak R; Buldak L; Mielanczyk L; Kukla M; Skonieczna M; Dulawa-Buldak A; Matysiak N; Zwirska-Korczala K
J Physiol Pharmacol; 2013 Jun; 64(3):377-85. PubMed ID: 23959735
[TBL] [Abstract][Full Text] [Related]
33. Cyclin-dependent kinases as therapeutic targets in melanoma.
Miller DM; Flaherty KT
Pigment Cell Melanoma Res; 2014 May; 27(3):351-65. PubMed ID: 24405945
[TBL] [Abstract][Full Text] [Related]
34. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
35. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
36. Drug targeting of oncogenic pathways in melanoma.
Fecher LA; Amaravadi RK; Schuchter LM; Flaherty KT
Hematol Oncol Clin North Am; 2009 Jun; 23(3):599-618, x. PubMed ID: 19464605
[TBL] [Abstract][Full Text] [Related]
37. Prospects for non-immunological molecular therapeutics in melanoma.
Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
[TBL] [Abstract][Full Text] [Related]
38. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
40. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
Favre G
Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
